Kronos Bio Key Executives
This section highlights Kronos Bio's key executives, including their titles and compensation details.
Find Contacts at Kronos Bio
(Showing 0 of )
Kronos Bio Earnings
This section highlights Kronos Bio's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Date:
May 08, 2025
Time:
Before Market
Est. EPS:
$-0.30
Status:
Unconfirmed
Last Earnings Results
Date:
March 18, 2025
EPS:
$-0.43
Est. EPS:
$-0.30
Revenue:
$2.27M
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Healthcare
Biotechnology
$0.84
Stock Price
$50.57M
Market Cap
10
Employees
San Mateo, CA
Location
Financial Statements
Access annual & quarterly financial statements for Kronos Bio, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $9.85M | $6.29M | $- | $- | $- |
| Cost of Revenue | $- | $- | $4.46M | $4.08M | $4.87M |
| Gross Profit | $9.85M | $6.29M | $-4.46M | $-4.08M | $-4.87M |
| Gross Profit Ratio | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $48.66M | $86.38M | $93.72M | $112.90M | $43.25M |
| General and Administrative Expenses | $24.62M | $41.74M | $43.40M | $38.49M | $14.79M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $24.62M | $41.74M | $43.40M | $38.49M | $14.79M |
| Other Expenses | $29.45M | $- | $- | $- | $-27.41M |
| Operating Expenses | $102.73M | $128.12M | $137.12M | $151.40M | $58.04M |
| Cost and Expenses | $102.73M | $128.12M | $137.12M | $151.40M | $58.04M |
| Interest Income | $6.81M | $9.16M | $3.91M | $320.00K | $898.00K |
| Interest Expense | $- | $- | $- | $- | $3.89M |
| Depreciation and Amortization | $1.72M | $2.14M | $4.46M | $4.08M | $4.87M |
| EBITDA | $-61.72M | $-119.69M | $-128.74M | $-147.00M | $-79.69M |
| EBITDA Ratio | -626.69% | -1903.53% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-92.89M | $-121.83M | $-137.12M | $-151.40M | $-58.04M |
| Operating Income Ratio | -943.21% | -1937.50% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $6.81M | $9.16M | $3.91M | $320.00K | $-30.40M |
| Income Before Tax | $-86.08M | $-112.67M | $-133.20M | $-151.08M | $-88.44M |
| Income Before Tax Ratio | -874.08% | -1791.87% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $-3.91M | $-1.98M | $-24.36M |
| Net Income | $-86.08M | $-112.67M | $-129.29M | $-149.10M | $-64.09M |
| Net Income Ratio | -874.08% | -1791.87% | 0.00% | 0.00% | 0.00% |
| EPS | $-1.43 | $-1.95 | $-2.30 | $-2.72 | $-1.19 |
| EPS Diluted | $-1.43 | $-1.95 | $-2.30 | $-2.72 | $-1.19 |
| Weighted Average Shares Outstanding | 60.07M | 57.74M | 56.20M | 54.75M | 54.07M |
| Weighted Average Shares Outstanding Diluted | 60.07M | 57.74M | 56.20M | 54.75M | 54.07M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.27M | $2.37M | $2.69M | $2.52M | $2.29M | $917.00K | $1.86M | $1.22M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $420.00K | $1.27M | $478.00K | $510.00K | $1.18M | $1.15M | $1.14M | $1.15M | $1.14M | $1.09M | $1.16M | $898.00K | $1.11M | $905.00K | $- | $- | $- | $- |
| Gross Profit | $2.27M | $2.37M | $2.27M | $1.25M | $1.81M | $407.00K | $685.00K | $67.00K | $-1.14M | $-1.15M | $-1.14M | $-1.09M | $-1.16M | $-898.00K | $-1.11M | $-905.00K | $- | $- | $- | $- |
| Gross Profit Ratio | 100.00% | 100.00% | 84.40% | 49.50% | 79.10% | 44.40% | 36.70% | 5.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $8.41M | $12.27M | $13.77M | $13.75M | $18.23M | $25.34M | $22.67M | $19.66M | $23.17M | $23.40M | $22.71M | $24.44M | $50.82M | $24.69M | $19.80M | $17.59M | $13.12M | $16.75M | $7.17M | $6.20M |
| General and Administrative Expenses | $4.92M | $5.82M | $6.37M | $7.51M | $10.93M | $9.40M | $11.36M | $10.06M | $10.51M | $10.13M | $10.82M | $11.93M | $11.59M | $8.98M | $9.34M | $8.58M | $7.96M | $4.05M | $1.62M | $1.15M |
| Selling and Marketing Expenses | $- | $- | $- | $-797.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $4.92M | $5.82M | $6.37M | $6.71M | $10.93M | $9.40M | $11.36M | $10.06M | $10.51M | $10.13M | $10.82M | $11.93M | $11.59M | $8.98M | $9.34M | $8.58M | $7.96M | $4.05M | $1.62M | $1.15M |
| Other Expenses | $16.09M | $- | $578.00K | $12.79M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-12.19M | $-15.21M | $- | $- |
| Operating Expenses | $29.42M | $18.09M | $20.71M | $20.46M | $29.15M | $34.74M | $34.03M | $29.71M | $33.68M | $33.54M | $33.53M | $36.37M | $62.41M | $33.67M | $29.14M | $26.18M | $21.09M | $20.81M | $8.80M | $7.35M |
| Cost and Expenses | $29.42M | $18.09M | $20.71M | $21.73M | $29.63M | $34.74M | $34.03M | $29.71M | $33.68M | $33.54M | $33.53M | $36.37M | $62.41M | $33.67M | $29.14M | $26.18M | $21.09M | $20.81M | $8.80M | $7.35M |
| Interest Income | $1.34M | $1.61M | $1.82M | $2.04M | $2.02M | $2.45M | $2.43M | $2.25M | $1.90M | $1.28M | $627.00K | $102.00K | $72.00K | $70.00K | $86.00K | $92.00K | $124.00K | $200.00K | $219.00K | $355.00K |
| Interest Expense | $- | $- | $- | $2.04M | $11.98M | $- | $- | $- | $- | $1.28M | $627.00K | $102.00K | $- | $- | $- | $- | $- | $3.89M | $- | $1.00K |
| Depreciation and Amortization | $409.00K | $412.00K | $420.00K | $1.27M | $478.00K | $510.00K | $1.18M | $1.15M | $1.14M | $1.15M | $1.14M | $1.09M | $1.16M | $898.00K | $1.11M | $905.00K | $300.00K | $196.00K | $183.00K | $160.00K |
| EBITDA | $-10.65M | $-15.30M | $-17.02M | $-18.73M | $-24.84M | $-33.31M | $-28.56M | $-27.92M | $-33.11M | $-32.97M | $-32.97M | $-35.81M | $-61.17M | $-33.15M | $-28.68M | $-25.73M | $-30.82M | $-34.65M | $-8.62M | $-6.77M |
| EBITDA Ratio | -469.34% | -645.74% | -633.37% | -711.75% | -1175.24% | -3688.66% | -1694.69% | -2333.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-27.15M | $-15.72M | $-18.02M | $-19.21M | $-27.34M | $-33.83M | $-32.17M | $-28.49M | $-33.68M | $-33.54M | $-33.53M | $-36.37M | $-62.41M | $-33.67M | $-29.14M | $-26.18M | $-21.09M | $-20.81M | $-8.80M | $-7.35M |
| Operating Income Ratio | -1196.21% | -663.12% | -670.50% | -762.22% | -1196.15% | -3688.66% | -1725.75% | -2333.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $1.34M | $1.61M | $1.82M | $2.04M | $2.02M | $2.45M | $2.43M | $2.25M | $1.90M | $1.28M | $627.00K | $102.00K | $72.00K | $70.00K | $86.00K | $92.00K | $-12.07M | $-18.90M | $219.00K | $354.00K |
| Income Before Tax | $-25.81M | $-14.11M | $-16.20M | $-29.96M | $-25.32M | $-31.37M | $-29.74M | $-26.24M | $-31.78M | $-32.26M | $-32.90M | $-36.26M | $-62.33M | $-33.60M | $-29.05M | $-26.09M | $-33.16M | $-39.71M | $-8.58M | $-7.00M |
| Income Before Tax Ratio | -1137.14% | -595.27% | -602.68% | -1188.81% | -1107.61% | -3421.37% | -1595.55% | -2148.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $- | $1.23M | $3.33M | $-510.00K | $456.92K | $-2.82M | $-2.63M | $-1.28M | $-627.00K | $-102.00K | $-474.00K | $70.00K | $86.00K | $92.00K | $-12.49M | $-11.33M | $219.00K | $355.00K |
| Net Income | $-25.81M | $-14.11M | $-16.20M | $-29.96M | $-25.32M | $-31.37M | $-29.74M | $-23.41M | $-29.15M | $-30.97M | $-32.28M | $-36.16M | $-62.33M | $-33.60M | $-29.05M | $-26.09M | $-33.16M | $-39.71M | $-8.58M | $-7.00M |
| Net Income Ratio | -1137.14% | -595.27% | -602.68% | -1188.81% | -1107.61% | -3421.37% | -1595.55% | -1917.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.43 | $-0.23 | $-0.27 | $-0.50 | $-0.43 | $-0.54 | $-0.52 | $-0.41 | $-0.52 | $-0.55 | $-0.58 | $-0.65 | $-1.13 | $-0.61 | $-0.53 | $-0.48 | $-0.70 | $-0.73 | $-0.17 | $-0.25 |
| EPS Diluted | $-0.43 | $-0.23 | $-0.27 | $-0.50 | $-0.43 | $-0.54 | $-0.52 | $-0.41 | $-0.52 | $-0.55 | $-0.58 | $-0.65 | $-1.13 | $-0.61 | $-0.53 | $-0.48 | $-0.70 | $-0.73 | $-0.17 | $-0.25 |
| Weighted Average Shares Outstanding | 60.34M | 60.31M | 60.10M | 59.52M | 58.27M | 58.15M | 57.40M | 57.15M | 56.52M | 56.32M | 56.12M | 55.84M | 55.36M | 54.98M | 54.51M | 54.15M | 47.22M | 54.20M | 51.33M | 28.45M |
| Weighted Average Shares Outstanding Diluted | 60.34M | 60.31M | 60.10M | 59.52M | 58.27M | 58.15M | 57.40M | 57.15M | 56.52M | 56.32M | 56.12M | 55.84M | 55.36M | 54.98M | 54.51M | 54.15M | 47.22M | 54.20M | 51.33M | 28.45M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $84.57M | $64.33M | $75.97M | $339.51M | $462.06M |
| Short Term Investments | $27.85M | $108.67M | $162.21M | $141.24M | $165.05M |
| Cash and Short Term Investments | $112.42M | $173.00M | $247.95M | $339.51M | $462.06M |
| Net Receivables | $- | $- | $572.00K | $816.00K | $612.00K |
| Inventory | $- | $- | $-10.33M | $-816.00K | $-49.61M |
| Other Current Assets | $2.81M | $5.78M | $5.53M | $6.70M | $5.89M |
| Total Current Assets | $115.23M | $178.78M | $244.29M | $347.55M | $419.80M |
| Property Plant Equipment Net | $7.00M | $29.91M | $37.69M | $41.78M | $40.97M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $1.99M | $9.76M | $2.03M | $49.00M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $2.14M | $2.60M | $3.19M | $112.00K | $2.19M |
| Total Non-Current Assets | $9.13M | $34.50M | $50.65M | $43.92M | $92.16M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $124.36M | $213.28M | $294.94M | $391.48M | $511.96M |
| Account Payables | $2.40M | $883.00K | $5.05M | $998.00K | $4.55M |
| Short Term Debt | $3.39M | $5.92M | $4.69M | $4.22M | $942.00K |
| Tax Payables | $26.00K | $133.00K | $40.00K | $- | $558.00K |
| Deferred Revenue | $1.86M | $9.58M | $- | $9.06M | $4.97M |
| Other Current Liabilities | $7.59M | $11.20M | $11.71M | $8.41M | $6.81M |
| Total Current Liabilities | $15.28M | $24.70M | $21.49M | $13.63M | $12.86M |
| Long Term Debt | $21.51M | $25.38M | $28.74M | $31.65M | $31.12M |
| Deferred Revenue Non-Current | $- | $4.13M | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $209.00K | $1.10M | $2.47M |
| Total Non-Current Liabilities | $21.51M | $29.51M | $28.95M | $32.75M | $33.59M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $36.78M | $54.20M | $50.44M | $46.38M | $46.45M |
| Preferred Stock | $- | $- | $- | $- | $511.96M |
| Common Stock | $60.00K | $59.00K | $57.00K | $56.00K | $54.00K |
| Retained Earnings | $-594.94M | $-508.86M | $-396.19M | $-262.98M | $-111.91M |
| Accumulated Other Comprehensive Income Loss | $9.00K | $19.00K | $-792.00K | $-39.00K | $-19.00K |
| Other Total Stockholders Equity | $682.45M | $667.86M | $641.42M | $608.06M | $577.39M |
| Total Stockholders Equity | $87.58M | $159.08M | $244.50M | $345.10M | $465.52M |
| Total Equity | $87.58M | $159.08M | $244.50M | $345.10M | $465.52M |
| Total Liabilities and Stockholders Equity | $124.36M | $213.28M | $294.94M | $391.48M | $511.96M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $124.36M | $213.28M | $294.94M | $391.48M | $511.96M |
| Total Investments | $27.85M | $110.66M | $171.97M | $141.24M | $214.05M |
| Total Debt | $24.90M | $28.27M | $31.09M | $33.76M | $32.06M |
| Net Debt | $-59.67M | $-36.05M | $-44.88M | $-305.75M | $-430.00M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $84.57M | $74.96M | $70.21M | $46.20M | $64.33M | $57.60M | $44.40M | $61.65M | $75.97M | $270.34M | $86.14M | $148.98M | $339.51M | $216.99M | $185.66M | $141.45M | $462.06M | $156.20M | $37.97M | $-92.18M |
| Short Term Investments | $27.85M | $49.89M | $66.44M | $105.79M | $108.67M | $129.11M | $175.06M | $164.76M | $162.21M | $190.77M | $181.75M | $154.16M | $141.24M | $181.39M | $231.22M | $257.48M | $165.05M | $55.07M | $43.50M | $184.37M |
| Cash and Short Term Investments | $112.42M | $124.86M | $136.65M | $151.98M | $173.00M | $186.71M | $219.46M | $241.29M | $247.95M | $270.34M | $267.89M | $303.14M | $339.51M | $398.38M | $416.88M | $398.92M | $462.06M | $211.26M | $81.46M | $92.18M |
| Net Receivables | $- | $- | $- | $- | $- | $492.00K | $343.00K | $516.00K | $572.00K | $607.00K | $544.00K | $661.00K | $816.00K | $1.05M | $1.22M | $1.27M | $612.00K | $217.00K | $174.00K | $- |
| Inventory | $- | $- | $- | $- | $- | $-492.00K | $-343.00K | $-15.40M | $-10.33M | $-12.09M | $- | $- | $- | $- | $- | $- | $-49.61M | $- | $- | $- |
| Other Current Assets | $2.81M | $3.06M | $4.54M | $6.38M | $5.78M | $4.36M | $4.32M | $5.35M | $5.53M | $5.31M | $5.48M | $6.28M | $6.70M | $2.29M | $5.74M | $4.33M | $5.89M | $725.00K | $165.00K | $- |
| Total Current Assets | $115.23M | $127.92M | $141.19M | $158.36M | $178.78M | $191.56M | $224.12M | $232.27M | $244.29M | $264.63M | $274.77M | $310.59M | $347.55M | $402.83M | $424.30M | $405.27M | $419.80M | $212.89M | $82.54M | $92.18M |
| Property Plant Equipment Net | $7.00M | $19.50M | $20.48M | $22.02M | $29.91M | $31.76M | $33.06M | $36.65M | $37.69M | $38.81M | $39.81M | $40.88M | $41.78M | $42.56M | $42.92M | $38.87M | $40.97M | $39.66M | $35.27M | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $1 | $2.03M | $4.01M | $11.67M | $244.00K | $14.88M | $9.76M | $12.09M | $24.49M | $12.25M | $2.03M | $2.03M | $2.38M | $41.68M | $49.00M | $4.77M | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $2.14M | $2.60M | $2.60M | $577.00K | $577.00K | $3.00M | $3.19M | $5.22M | $3.19M | $2.14M | $2.14M | $2.14M | $112.00K | $112.00K | $2.14M | $2.14M | $2.19M | $5.23M | $2.73M | $-92.18M |
| Total Non-Current Assets | $9.13M | $22.11M | $23.09M | $24.62M | $34.50M | $46.43M | $36.49M | $56.76M | $50.65M | $53.04M | $66.45M | $55.27M | $43.92M | $44.70M | $47.44M | $82.69M | $92.16M | $49.66M | $37.99M | $-92.18M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $124.36M | $150.02M | $164.27M | $182.98M | $213.28M | $237.99M | $260.62M | $289.02M | $294.94M | $317.67M | $341.22M | $365.86M | $391.48M | $447.53M | $471.74M | $487.96M | $511.96M | $262.56M | $120.53M | $- |
| Account Payables | $2.40M | $1.28M | $990.00K | $2.23M | $883.00K | $4.08M | $2.68M | $6.04M | $5.05M | $1.46M | $3.29M | $4.72M | $998.00K | $3.94M | $3.34M | $3.59M | $4.55M | $4.44M | $2.46M | $- |
| Short Term Debt | $3.39M | $3.26M | $7.24M | $3.02M | $5.79M | $6.53M | $6.08M | $6.06M | $2.35M | $4.48M | $5.41M | $5.00M | $2.11M | $3.46M | $2.27M | $1.64M | $942.00K | $175.26M | $2.19M | $- |
| Tax Payables | $26.00K | $- | $- | $- | $133.00K | $- | $- | $40.00K | $40.00K | $- | $- | $50.00K | $- | $29.00K | $146.00K | $4.00K | $558.00K | $38.00K | $25.00K | $- |
| Deferred Revenue | $1.86M | $5.16M | $7.53M | $8.67M | $9.58M | $8.58M | $8.82M | $8.65M | $- | $- | $- | $- | $9.06M | $7.35M | $6.52M | $4.28M | $4.97M | $1.78M | $843.00K | $- |
| Other Current Liabilities | $7.59M | $5.68M | $885.00K | $5.12M | $8.31M | $6.49M | $4.48M | $4.47M | $14.05M | $14.16M | $9.53M | $7.30M | $10.52M | $7.35M | $7.32M | $6.05M | $6.81M | $3.87M | $1.51M | $- |
| Total Current Liabilities | $15.28M | $15.38M | $16.64M | $19.03M | $24.70M | $25.67M | $22.05M | $25.26M | $21.49M | $20.11M | $18.23M | $17.08M | $13.63M | $14.77M | $13.08M | $11.29M | $12.86M | $183.60M | $6.19M | $- |
| Long Term Debt | $21.51M | $22.54M | $23.51M | $24.46M | $25.38M | $26.28M | $27.13M | $27.95M | $28.74M | $29.53M | $30.26M | $30.96M | $31.65M | $32.33M | $32.84M | $29.39M | $31.12M | $152.39M | $28.51M | $- |
| Deferred Revenue Non-Current | $- | $- | $974.00K | $2.52M | $4.13M | $7.42M | $8.09M | $10.12M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $-2.52M | $-25.38M | $-7.42M | $-8.09M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $975.00K | $- | $- | $- | $- | $- | $87.00K | $209.00K | $350.00K | $490.00K | $795.00K | $1.10M | $1.41M | $1.71M | $2.02M | $2.47M | $2.84M | $912.00K | $- |
| Total Non-Current Liabilities | $21.51M | $23.51M | $24.49M | $26.98M | $29.51M | $33.70M | $35.22M | $38.16M | $28.95M | $29.88M | $30.75M | $31.76M | $32.75M | $33.73M | $34.56M | $31.42M | $33.59M | $155.23M | $29.42M | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $36.78M | $38.90M | $41.13M | $46.01M | $54.20M | $59.37M | $57.27M | $63.42M | $50.44M | $49.98M | $48.98M | $48.84M | $46.38M | $48.51M | $47.63M | $42.70M | $46.45M | $338.84M | $35.61M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $447.53M | $471.74M | $487.96M | $111.91M | $122.91M | $122.91M | $122.91M |
| Common Stock | $60.00K | $60.00K | $60.00K | $60.00K | $59.00K | $58.00K | $58.00K | $57.00K | $57.00K | $56.00K | $56.00K | $56.00K | $56.00K | $55.00K | $55.00K | $54.00K | $54.00K | $6.00K | $29.00K | $- |
| Retained Earnings | $-594.94M | $-569.13M | $-555.02M | $-538.82M | $-508.86M | $-483.54M | $-452.17M | $-422.43M | $-396.19M | $-364.41M | $-332.15M | $-299.25M | $-262.98M | $-200.65M | $-167.05M | $-137.99M | $-111.91M | $-78.75M | $-39.04M | $- |
| Accumulated Other Comprehensive Income Loss | $9.00K | $24.00K | $-36.00K | $-49.00K | $19.00K | $-255.00K | $-469.00K | $-360.00K | $-792.00K | $-1.05M | $-661.00K | $-170.00K | $-39.00K | $7.00K | $6.00K | $-23.00K | $-19.00K | $47.00K | $164.00K | $-23.20M |
| Other Total Stockholders Equity | $682.45M | $680.17M | $678.14M | $675.78M | $667.86M | $662.36M | $655.92M | $648.33M | $641.42M | $633.09M | $625.00M | $616.38M | $608.06M | $599.61M | $591.09M | $583.22M | $577.39M | $-122.91M | $123.79M | $- |
| Total Stockholders Equity | $87.58M | $111.13M | $123.15M | $136.97M | $159.08M | $178.62M | $203.34M | $225.60M | $244.50M | $267.69M | $292.24M | $317.02M | $345.10M | $399.02M | $424.11M | $445.26M | $465.52M | $-76.28M | $84.93M | $99.70M |
| Total Equity | $87.58M | $111.13M | $123.15M | $136.97M | $159.08M | $178.62M | $203.34M | $225.60M | $244.50M | $267.69M | $292.24M | $317.02M | $345.10M | $399.02M | $424.11M | $445.26M | $465.52M | $-76.28M | $84.93M | $99.70M |
| Total Liabilities and Stockholders Equity | $124.36M | $150.02M | $164.27M | $182.98M | $213.28M | $237.99M | $260.62M | $289.02M | $294.94M | $317.67M | $341.22M | $365.86M | $391.48M | $447.53M | $471.74M | $487.96M | $511.96M | $262.56M | $120.53M | $99.70M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $124.36M | $150.02M | $164.27M | $182.98M | $213.28M | $237.99M | $260.62M | $289.02M | $294.94M | $317.67M | $341.22M | $365.86M | $391.48M | $447.53M | $471.74M | $487.96M | $511.96M | $262.56M | $120.53M | $99.70M |
| Total Investments | $27.85M | $49.89M | $66.44M | $107.81M | $112.69M | $140.78M | $175.31M | $179.64M | $171.97M | $202.86M | $206.24M | $166.40M | $141.24M | $181.39M | $233.60M | $299.16M | $214.05M | $59.84M | $43.50M | $184.37M |
| Total Debt | $24.90M | $25.80M | $27.13M | $27.47M | $28.27M | $29.54M | $30.16M | $30.98M | $31.09M | $31.77M | $32.96M | $33.47M | $33.76M | $34.05M | $33.98M | $30.22M | $32.06M | $204.74M | $30.70M | $- |
| Net Debt | $-59.67M | $-49.17M | $-43.08M | $-18.72M | $-36.05M | $-28.06M | $-14.23M | $-30.67M | $-44.88M | $-238.58M | $-53.18M | $-115.51M | $-305.75M | $-182.94M | $-151.68M | $-111.23M | $-430.00M | $48.55M | $-7.27M | $92.18M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-86.08M | $-112.67M | $-133.20M | $-151.08M | $-88.44M |
| Depreciation and Amortization | $1.72M | $2.14M | $2.27M | $1.98M | $839.00K |
| Deferred Income Tax | $- | $- | $- | $4.00M | $326.00K |
| Stock Based Compensation | $9.22M | $24.98M | $31.14M | $26.21M | $3.75M |
| Change in Working Capital | $-17.89M | $5.88M | $6.18M | $-1.62M | $6.46M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $1.52M | $-4.15M | $4.03M | $-3.19M | $2.81M |
| Other Working Capital | $-19.42M | $10.02M | $2.15M | $1.57M | $3.65M |
| Other Non Cash Items | $27.60M | $1.10M | $2.69M | $2.59M | $39.15M |
| Net Cash Provided by Operating Activities | $-65.44M | $-78.58M | $-90.93M | $-117.92M | $-37.91M |
| Investments in Property Plant and Equipment | $-4.00K | $-679.00K | $-577.00K | $-4.26M | $-9.57M |
| Acquisitions Net | $- | $- | $31.64M | $-67.98M | $150.67M |
| Purchases of Investments | $-89.23M | $-212.96M | $-367.12M | $-177.73M | $-229.33M |
| Sales Maturities of Investments | $174.67M | $280.00M | $335.48M | $245.72M | $78.66M |
| Other Investing Activities | $- | $-1 | $-31.64M | $67.98M | $-150.67M |
| Net Cash Used for Investing Activities | $85.44M | $66.37M | $-32.22M | $63.72M | $-160.24M |
| Debt Repayment | $- | $- | $- | $-5.00K | $151.24M |
| Common Stock Issued | $- | $567.00K | $851.00K | $4.46M | $263.73M |
| Common Stock Repurchased | $244.00K | $538.00K | $380.00K | $1.34M | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $245.00K | $567.00K | $851.00K | $4.46M | $264.37M |
| Net Cash Used Provided by Financing Activities | $245.00K | $567.00K | $851.00K | $4.46M | $415.61M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $20.25M | $-11.65M | $-122.30M | $-49.74M | $217.47M |
| Cash at End of Period | $86.60M | $66.35M | $78.00M | $200.30M | $250.04M |
| Cash at Beginning of Period | $66.35M | $78.00M | $200.30M | $250.04M | $32.57M |
| Operating Cash Flow | $-65.44M | $-78.58M | $-90.93M | $-117.92M | $-37.91M |
| Capital Expenditure | $-4.00K | $-679.00K | $-577.00K | $-4.26M | $-9.57M |
| Free Cash Flow | $-65.44M | $-79.26M | $-91.50M | $-122.18M | $-47.48M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-25.81M | $-14.11M | $-16.20M | $-29.96M | $-25.32M | $-31.37M | $-29.74M | $-26.24M | $-31.78M | $-32.26M | $-32.90M | $-36.26M | $-62.33M | $-33.60M | $-29.05M | $-26.09M | $-33.16M | $-39.71M | $-8.58M | $-7.00M |
| Depreciation and Amortization | $409.00K | $-385.00K | $420.00K | $1.27M | $478.00K | $510.00K | $579.00K | $569.00K | $574.00K | $571.00K | $564.00K | $557.00K | $546.00K | $523.00K | $464.00K | $444.00K | $300.00K | $196.00K | $183.00K | $160.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-9.33M | $-1.37M | $1.43M | $- | $- | $- | $- | $- | $822.00K | $1.10M | $1.13M | $943.00K | $221.00K | $41.00K | $- | $- |
| Stock Based Compensation | $1.66M | $2.03M | $2.20M | $3.33M | $5.17M | $6.30M | $6.91M | $6.61M | $7.69M | $7.46M | $8.21M | $7.79M | $7.40M | $7.14M | $6.43M | $5.24M | $2.02M | $1.25M | $293.00K | $188.00K |
| Change in Working Capital | $-5.27M | $11.89M | $-3.29M | $-8.59M | $-5.29M | $2.60M | $-5.00M | $13.57M | $971.00K | $1.56M | $604.00K | $3.04M | $-5.85M | $4.17M | $76.00K | $-14.00K | $567.00K | $4.27M | $2.06M | $-436.00K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $1.12M | $289.00K | $-1.24M | $1.35M | $-3.20M | $1.60M | $-3.56M | $1.00M | $3.62M | $-1.88M | $-1.38M | $3.67M | $-2.54M | $838.00K | $-289.00K | $-1.20M | $1.68M | $835.00K | $538.00K | $-244.00K |
| Other Working Capital | $-6.39M | $11.60M | $-2.06M | $-9.94M | $-2.09M | $993.00K | $-1.44M | $12.57M | $-2.65M | $3.44M | $1.99M | $-630.00K | $-3.31M | $3.33M | $365.00K | $1.19M | $-1.11M | $3.43M | $1.52M | $-192.00K |
| Other Non Cash Items | $16.18M | $-11.79M | $542.00K | $14.58M | $9.27M | $752.00K | $796.00K | $-456.00K | $20.00K | $267.00K | $1.01M | $1.39M | $891.00K | $533.00K | $688.00K | $477.00K | $14.42M | $23.67M | $1.11M | $17.00K |
| Net Cash Provided by Operating Activities | $-12.84M | $-12.37M | $-16.33M | $-23.90M | $-25.02M | $-22.59M | $-25.02M | $-5.95M | $-22.53M | $-22.39M | $-22.52M | $-23.48M | $-58.52M | $-20.14M | $-20.26M | $-19.00M | $-15.63M | $-10.29M | $-4.93M | $-7.07M |
| Investments in Property Plant and Equipment | $-4.00K | $7.00K | $- | $-7.00K | $-31.00K | $-214.00K | $-308.00K | $-126.00K | $-52.00K | $-73.00K | $-86.00K | $-366.00K | $-478.00K | $-926.00K | $-1.35M | $-1.50M | $-3.68M | $-4.17M | $-1.09M | $-626.00K |
| Acquisitions Net | $- | $- | $- | $- | $-31.59M | $-36.00M | $-5.68M | $6.23M | $-31.79M | $-3.18M | $40.64M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-10.46M | $-23.62M | $-6.40M | $-48.75M | $-42.14M | $-30.50M | $-37.73M | $-102.59M | $-59.94M | $-91.06M | $-121.57M | $-94.54M | $-14.12M | $-22.42M | $-15.14M | $-126.06M | $-188.12M | $-33.05M | $-5.85M | $-2.31M |
| Sales Maturities of Investments | $32.82M | $40.74M | $46.58M | $54.53M | $73.73M | $66.50M | $43.41M | $96.37M | $91.73M | $94.24M | $80.93M | $68.57M | $53.35M | $73.44M | $79.52M | $39.42M | $33.05M | $16.43M | $20.93M | $8.24M |
| Other Investing Activities | $- | $- | $- | $5.78M | $31.59M | $36.00M | $5.68M | $-6.23M | $31.79M | $3.18M | $-40.64M | $-25.97M | $39.23M | $51.02M | $64.38M | $-86.64M | $-155.07M | $-16.62M | $15.09M | $5.94M |
| Net Cash Used for Investing Activities | $22.36M | $17.13M | $40.18M | $5.77M | $31.56M | $35.79M | $5.37M | $-6.36M | $31.74M | $3.11M | $-40.73M | $-26.34M | $38.75M | $50.09M | $63.03M | $-88.15M | $-158.75M | $-20.78M | $13.99M | $5.31M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-5.00K | $-8.00K | $151.27M | $-8.00K | $-8.00K |
| Common Stock Issued | $- | $- | $- | $- | $191.00K | $- | $376.00K | $- | $-716.00K | $628.00K | $410.00K | $529.00K | $1.05M | $1.38M | $1.44M | $590.00K | $263.31M | $278.00K | $113.00K | $20.00K |
| Common Stock Repurchased | $- | $162.00K | $- | $- | $538.00K | $- | $- | $- | $-716.00K | $- | $- | $- | $521.00K | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $82.00K | $-1.00K | $164.00K | $- | $191.00K | $- | $376.00K | $- | $-716.00K | $628.00K | $410.00K | $529.00K | $1.05M | $1.38M | $1.44M | $- | $2.89M | $-2.25M | $- | $- |
| Net Cash Used Provided by Financing Activities | $82.00K | $-1.00K | $164.00K | $- | $191.00K | $- | $376.00K | $- | $-716.00K | $628.00K | $410.00K | $529.00K | $1.05M | $1.38M | $1.44M | $585.00K | $266.20M | $149.30M | $105.00K | $12.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $9.61M | $4.76M | $24.01M | $-18.13M | $6.73M | $13.20M | $-19.27M | $-12.30M | $8.49M | $-18.66M | $-62.84M | $-49.29M | $-18.72M | $31.34M | $44.21M | $-106.56M | $91.81M | $118.23M | $9.17M | $-1.74M |
| Cash at End of Period | $86.60M | $76.99M | $70.21M | $46.20M | $64.33M | $59.62M | $46.42M | $65.70M | $78.00M | $69.51M | $88.17M | $151.00M | $200.30M | $219.02M | $187.68M | $143.47M | $250.04M | $158.22M | $39.99M | $30.83M |
| Cash at Beginning of Period | $76.99M | $72.23M | $46.20M | $64.33M | $57.60M | $46.42M | $65.70M | $78.00M | $69.51M | $88.17M | $151.00M | $200.30M | $219.02M | $187.68M | $143.47M | $250.04M | $158.22M | $39.99M | $30.83M | $32.57M |
| Operating Cash Flow | $-12.84M | $-12.37M | $-16.33M | $-23.90M | $-25.02M | $-22.59M | $-25.02M | $-5.95M | $-22.53M | $-22.39M | $-22.52M | $-23.48M | $-58.52M | $-20.14M | $-20.26M | $-19.00M | $-15.63M | $-10.29M | $-4.93M | $-7.07M |
| Capital Expenditure | $-4.00K | $7.00K | $- | $-7.00K | $-31.00K | $-214.00K | $-308.00K | $-126.00K | $-52.00K | $-73.00K | $-86.00K | $-366.00K | $-478.00K | $-926.00K | $-1.35M | $-1.50M | $-3.68M | $-4.17M | $-1.09M | $-626.00K |
| Free Cash Flow | $-12.84M | $-12.36M | $-16.33M | $-23.91M | $-25.05M | $-22.80M | $-25.33M | $-6.07M | $-22.58M | $-22.47M | $-22.61M | $-23.85M | $-59.00M | $-21.07M | $-21.61M | $-20.50M | $-19.31M | $-14.45M | $-6.03M | $-7.69M |
Kronos Bio Dividends
Explore Kronos Bio's dividend history, including dividend yield, payout ratio, and historical payments.
Kronos Bio News
Read the latest news about Kronos Bio, including recent articles, headlines, and updates.
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated exposures –
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
– Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity – – Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity –
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease
– KB-7898, a p300 KAT inhibitor, is the Company's first development candidate for autoimmune diseases and originates from its proprietary discovery engine that decodes complex transcription factor regulatory networks –
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
– Through selective inhibition of proinflammatory transcription, p300 KAT inhibition modulates the activity and function of multiple pro-inflammatory signaling pathways that drive chronic inflammatory diseases –
After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
The heavy selling pressure might have exhausted for Kronos Bio (KRON) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Kronos Bio Announces Participation in Medical and Investor Conferences in September
SAN MATEO, Calif., and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the following upcoming conferences:
After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
Kronos Bio (KRON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
— KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation — — Company expects to provide an efficacy update on this expansion cohort in 1H 2025 — SAN MATEO, Calif. and CAMBRIDGE, Mass.
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that the company would participate in three upcoming healthcare conferences and events. Norbert Bischofberger, Ph.D., president and chief executive officer, will represent the company at these events.
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it has appointed Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer effective June 3, 2024. Dr. Knobelman will oversee the finance, accounting, business development, investor relations and corporate strategy functions.
Down -5.63% in 4 Weeks, Here's Why Kronos Bio (KRON) Looks Ripe for a Turnaround
Kronos Bio (KRON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Kronos Bio Reports First-Quarter 2024 Financial Results
— $152.0 million cash runway into the second half of 2026 — — A study update on KB-0742-1001 will be presented at the upcoming American Society of Clinical Oncology (ASCO); expansion cohorts at new dose schedule remain on track to open in Q3 2024 — — KB-9558 remains on track with IND-enabling studies expected to complete in 2024 with first-in-human study anticipated to commence in the first half of 2025 — SAN MATEO, Calif. and CAMBRIDGE, Mass.
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half of 2025
How Does Kronos Stock Look After Its 15% Rise Last Week?
Kronos Worldwide KRO (NYSE: KRO), a titanium dioxide pigments (TiO2) producer and marketer, has gained around 15% in a week, considerably outperforming the broader Russell 2000 index which remains down by 0.2% over the same period. So what's driving the recent surge in the stock?
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California.
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 44th Annual Cowen Health Care Conference, taking place March 4-6, 2024, in Boston, Massachusetts.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for KRON.